Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Autor: Georgina L. Ryland, Masayuki Umeda, Linda Holmfeldt, Sören Lehmann, Morten Krogh Herlin, Jing Ma, Mahsa Khanlari, Jeffrey E. Rubnitz, Rhonda E. Ries, Hansen J. Kosasih, Paul G. Ekert, Hwee Ngee Goh, Ing S. Tiong, Sean M. Grimmond, Claudia Haferlach, Ryan B. Day, Timothy J. Ley, Soheil Meshinchi, Xiaotu Ma, Piers Blombery, Jeffery M. Klco

Publikováno v: Ryland, G, Umeda, M, Holmfeldt, L, Lehmann, S, Herlin, M K, Ma, J J, Khanlari, M, Rubnitz, J E, Ries, R E, Kosasih, H J, Ekert, P G, Goh, H N, Tiong, I S, Grimmond, S M, Haferlach, C, Day, R B, Ley, T J, Meshinchi, S, Ma, X, Blombery, P & Klco, J M 2023, ' Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions ', Blood, vol. 141, no. 7, pp. 800-805 . https://doi.org/10.1182/blood.2022017874

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f7b10821fb0a0a1f6a90fd2b733b17a
https://doi.org/10.1182/blood.2022017874

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Autor: Chong Chyn Chua, Sun Loo, John Reynolds, Ing S Tiong, Chun Yew Fong, Stephen B Ting, Shaun Fleming, Andrew W Roberts, Andrew H Wei

Publikováno v: Blood. 140:1708-1710

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ede2344f692bd470985bb10b0c1ab10
https://doi.org/10.1182/blood-2022-165021

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Autor: Ing S Tiong, Devendra Hiwase, Emad Uddin Abro, Ashish Bajel, Emma Palfreyman, Sun Loo, Shaun Fleming, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H Wei

Publikováno v: Blood. 140:1453-1455

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0b4915a15574ecf2006bd1ff8d4ad9c
https://doi.org/10.1182/blood-2022-163041

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Autor: Andrew H Wei, Harry J Iland, John Reynolds, Sun Loo, Chong Chyn Chua, David Westerman, Ing S Tiong, Adam Ivey, Piers Blombery, Natasha S Anstee, Rachel M Koldej, David J. Curtis, David Kipp, David Ritchie, David M Ross, Amanda Souza, Jenny Collins, Ashish Bajel, Carolyn Grove, Paula Marlton, Andrew W Roberts, Naveen Pemmaraju, Keyur P. Patel, Sanam Loghavi, Marina Konopleva, Naval Daver, Courtney D. DiNardo

Publikováno v: Blood. 140:3341-3343

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::99df831951fae16b6de4c6578e52b80a
https://doi.org/10.1182/blood-2022-167837

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia

Autor: Donia M. Moujalled, Fiona C. Brown, Chong Chyn Chua, Michael A. Dengler, Giovanna Pomilio, Natasha S. Anstee, Veronique Litalien, Ella Thompson, Thomas Morley, Sarah MacRaild, Ing S. Tiong, Rhiannon Morris, Karen Dun, Adrian Zordan, Jaynish Shah, Sebastien Banquet, Ensar Halilovic, Erick Morris, Marco J. Herold, Guillaume Lessene, Jerry M. Adams, David C. S. Huang, Andrew W. Roberts, Piers Blombery, Andrew H. Wei

Publikováno v: Blood.

Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role of venetoclax in combination with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb6a5b8bf055c55da30516d405210eb0
https://pubmed.ncbi.nlm.nih.gov/36219880